Fighting fibrosis

Abstract

Improving target selectivity and defining cell phenotypes may improve the odds of finding therapies for fibrosis.

Fig. 1. Cast of characters.

Pathways targeted by pulmonary fibrosis drugs and drug candidates are primarily inhibitors of relevant targeting signaling pathways (the autotaxin and TGFβ pathways), as well as the pathway that reprograms epithelial cells. Figure modified with permission from Y. Fang, J. Tian, Y. Fan & P. Cao, Mol. Biol. Rep. 47, 9811–9820 (2020), Springer Nature.